.png)
bit.bio launches ioAstrocytes 2.0 for reproducible all-human neuron–astrocyte networks
07.10.2026
bit.bio brings human cardiomyocytes to its drug discovery portfolio through partnership with myriamed
bit.bio partners with myriamed to expand cell portfolio with functional human cardiomyocytes, providing researchers access to adva...
Two new disease models for Duchenne muscular dystrophy
bit.bio launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...
bit.bio launches new wild type cell product ioMicroglia
ioMicroglia™ is set to accelerate research and drug discovery for neurodegenerative disease.
Product launch for our first disease model for studying Parkinson’s
bit.bio launches the first commercially available human iPSC-derived disease models for Parkinson’s disease that carry the PRKN R2...
Early access product launch for ioSensory Neurons
bit.bio launches early access to ioSensory Neurons for chronic pain research and therapeutics development for peripheral neuropath...
New cell products for neurodegenerative disease
Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.
bit.bio launches Huntington’s disease human cell model
The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.
New product launch | ioSkeletal Myocytes
This is the first supply of consistent, scalable, human muscle cells, providing transformative new models for drug discovery.